223 related articles for article (PubMed ID: 17579623)
1. Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial.
Atmaca A; Al-Batran SE; Maurer A; Neumann A; Heinzel T; Hentsch B; Schwarz SE; Hövelmann S; Göttlicher M; Knuth A; Jäger E
Br J Cancer; 2007 Jul; 97(2):177-82. PubMed ID: 17579623
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study.
Münster P; Marchion D; Bicaku E; Schmitt M; Lee JH; DeConti R; Simon G; Fishman M; Minton S; Garrett C; Chiappori A; Lush R; Sullivan D; Daud A
J Clin Oncol; 2007 May; 25(15):1979-85. PubMed ID: 17513804
[TBL] [Abstract][Full Text] [Related]
3. Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial.
Daud AI; Dawson J; DeConti RC; Bicaku E; Marchion D; Bastien S; Hausheer FA; Lush R; Neuger A; Sullivan DM; Munster PN
Clin Cancer Res; 2009 Apr; 15(7):2479-87. PubMed ID: 19318485
[TBL] [Abstract][Full Text] [Related]
4. A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia.
Gimsing P; Hansen M; Knudsen LM; Knoblauch P; Christensen IJ; Ooi CE; Buhl-Jensen P
Eur J Haematol; 2008 Sep; 81(3):170-6. PubMed ID: 18510700
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of valproic acid and lenalidomide in patients with advanced cancer.
Bilen MA; Fu S; Falchook GS; Ng CS; Wheler JJ; Abdelrahim M; Erguvan-Dogan B; Hong DS; Tsimberidou AM; Kurzrock R; Naing A
Cancer Chemother Pharmacol; 2015 Apr; 75(4):869-74. PubMed ID: 25666183
[TBL] [Abstract][Full Text] [Related]
6. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
[TBL] [Abstract][Full Text] [Related]
7. Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies.
Falchook GS; Fu S; Naing A; Hong DS; Hu W; Moulder S; Wheler JJ; Sood AK; Bustinza-Linares E; Parkhurst KL; Kurzrock R
Invest New Drugs; 2013 Oct; 31(5):1192-200. PubMed ID: 23907406
[TBL] [Abstract][Full Text] [Related]
8. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma.
Ryan QC; Headlee D; Acharya M; Sparreboom A; Trepel JB; Ye J; Figg WD; Hwang K; Chung EJ; Murgo A; Melillo G; Elsayed Y; Monga M; Kalnitskiy M; Zwiebel J; Sausville EA
J Clin Oncol; 2005 Jun; 23(17):3912-22. PubMed ID: 15851766
[TBL] [Abstract][Full Text] [Related]
9. In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor.
Neri P; Tagliaferri P; Di Martino MT; Calimeri T; Amodio N; Bulotta A; Ventura M; Eramo PO; Viscomi C; Arbitrio M; Rossi M; Caraglia M; Munshi NC; Anderson KC; Tassone P
Br J Haematol; 2008 Nov; 143(4):520-31. PubMed ID: 18986388
[TBL] [Abstract][Full Text] [Related]
10. Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia.
Bug G; Ritter M; Wassmann B; Schoch C; Heinzel T; Schwarz K; Romanski A; Kramer OH; Kampfmann M; Hoelzer D; Neubauer A; Ruthardt M; Ottmann OG
Cancer; 2005 Dec; 104(12):2717-25. PubMed ID: 16294345
[TBL] [Abstract][Full Text] [Related]
11. The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia.
Kuendgen A; Schmid M; Schlenk R; Knipp S; Hildebrandt B; Steidl C; Germing U; Haas R; Dohner H; Gattermann N
Cancer; 2006 Jan; 106(1):112-9. PubMed ID: 16323176
[TBL] [Abstract][Full Text] [Related]
12. HDAC inhibition delays cell cycle progression of human bladder cancer cells in vitro.
Vallo S; Xi W; Hudak L; Juengel E; Tsaur I; Wiesner C; Haferkamp A; Blaheta RA
Anticancer Drugs; 2011 Nov; 22(10):1002-9. PubMed ID: 21822119
[TBL] [Abstract][Full Text] [Related]
13. A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with Advanced solid malignancies.
Siu LL; Rowinsky EK; Hammond LA; Weiss GR; Hidalgo M; Clark GM; Moczygemba J; Choi L; Linnartz R; Barbet NC; Sklenar IT; Capdeville R; Gan G; Porter CW; Von Hoff DD; Eckhardt SG
Clin Cancer Res; 2002 Jul; 8(7):2157-66. PubMed ID: 12114416
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of pomalidomide given for patients with advanced solid tumors.
Cooney MM; Nock C; Bokar J; Krishnamurthi S; Gibbons J; Rodal MB; Ness A; Remick SC; Dreicer R; Dowlati A
Cancer Chemother Pharmacol; 2012 Nov; 70(5):755-61. PubMed ID: 22875080
[TBL] [Abstract][Full Text] [Related]
15. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D
Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692
[TBL] [Abstract][Full Text] [Related]
16. Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours.
Trocòniz IF; Garrido MJ; Segura C; Cendrós JM; Principe P; Peraire C; Obach R
Cancer Chemother Pharmacol; 2006 Jun; 57(6):727-35. PubMed ID: 16261364
[TBL] [Abstract][Full Text] [Related]
17. Valproic acid-mediated neuroprotection in intracerebral hemorrhage via histone deacetylase inhibition and transcriptional activation.
Sinn DI; Kim SJ; Chu K; Jung KH; Lee ST; Song EC; Kim JM; Park DK; Kun Lee S; Kim M; Roh JK
Neurobiol Dis; 2007 May; 26(2):464-72. PubMed ID: 17398106
[TBL] [Abstract][Full Text] [Related]
18. Effects of valproic acid in combination with S-1 on advanced pancreatobiliary tract cancers: clinical study phases I/II.
Iwahashi S; Utsunomiya T; Imura S; Morine Y; Ikemoto T; Arakawa Y; Saito Y; Ishikawa D; Shimada M
Anticancer Res; 2014 Sep; 34(9):5187-91. PubMed ID: 25202113
[TBL] [Abstract][Full Text] [Related]
19. Concurrent phase I trials of intravenous interleukin 6 in solid tumor patients: reversible dose-limiting neurological toxicity.
Sosman JA; Aronson FR; Sznol M; Atkins MB; Dutcher JP; Weiss GR; Isaacs RE; Margolin KA; Fisher RI; Ernest ML; Mier J; Oleksowicz L; Eckhardt JR; Levitt D; Doroshow JH
Clin Cancer Res; 1997 Jan; 3(1):39-46. PubMed ID: 9815535
[TBL] [Abstract][Full Text] [Related]
20. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
